Actinogen Medical Limited (ACW.AX)
| Previous close | 0.0660 |
| Open | 0.0680 |
| Bid | 0.0660 x 194091900 |
| Ask | 0.0680 x 380640100 |
| Day's range | 0.0660 - 0.0680 |
| 52-week range | 0.0400 - 0.1600 |
| Volume | |
| Avg. volume | 697,447 |
| Market cap | 125.348M |
| Beta (5Y monthly) | 2.12 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0100 |
| Earnings date | 22 Feb 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 0.15 |
- PR Newswire
Actinogen presents positive Phase 2a Xanamem data in at ADPD™ Alzheimer's and Parkinson's diseases conference
Actinogen Medical ASX: ACW ("ACW" or "the Company") is pleased to announce that its Chief Medical Officer, Dr Dana Hilt will make an oral presentation to the International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (ADPD™ 2023) later today in Gothenburg, Sweden.
- PR Newswire
FDA agrees to Actinogen six-month Phase 2b Alzheimer's Disease trial
Actinogen Medical Limited (ASX: ACW) is pleased to announce receipt today of agreement from the US Food and Drug Administration (FDA) to proceed with its six-month, Phase 2b, placebo-controlled clinical trial of Xanamem in patients with early stages of Alzheimer's Disease (AD).
- PR Newswire
Actinogen announces first patient treated in depression and cognitive impairment Phase 2 clinical trial
Actinogen Medical Limited (ASX: ACW) is pleased to announce that the first patient has been randomized and treated in the XanaCIDD Phase 2 depression clinical trial that will measure the effects of Xanamem on safety, cognitive performance and depression in patients who are inadequately treated by their anti-depressant medication and have both depressive symptoms and cognitive impairment.
